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1. Introduction
The care of patients with chronic renal insufficiency continues to be complicated by significant
cardiovascular dysfunction causing substantial morbidity and mortality. These patients
develop cardiovascular disease that is characterized by left ventricular dysfunction and left
ventricular hypertrophy (LVH). It has been demonstrated that patients with chronic renal
insufficiency develop elevated levels of cardiotonic steroids (CTS) such as marinobufagenin
(MBG) in an effort to promote natriuresis and resolve the volume expansion associated with
renal insufficiency and cardiac failure. In this review we will try to elucidate the mechanisms
involved in the pathogenesis of uremic cardiomyopathy and the role of CTS in cardiac fibrosis.
2. Renal failure and cardiotonic steroids
Patients with renal insufficiency continue to demonstrate significantly high risk of cardiovas‐
cular disease with an associated mortality exceeding 50% cardiovascular causes including
sudden cardiac death and heart failure [1]. While end stage renal disease confers a high risk
of complications those patients with a more modest degree of renal insufficiency (stage 2 and
stage 3) continue to have high risk of cardiac events including heart failure, arrhythmia,
coronary events and sudden cardiac death all independent of traditional risk factors such as
diabetes, hypertension and hyperlipidemia. The cardiac dysfunction most commonly manifest
as diastolic dysfunction and left ventricular hypertrophy although systolic dysfunction can
occur as a natural progression [2].
In the past there has been substantial interest and research related to digitalis-like substances
(DLS) their accumulation in chronic renal failure and pathology associated with elevated
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circulating levels. Patients with chronic renal failure frequently developed antibodies to
digoxin despite no administration of the drug [3, 4]. These DLS were later characterized as
cardiotonic steroids and are significantly elevated due to decreased glomerular filtration and
increased endogenous production. These endogenous ligands have been found to significantly
alter renal sodium handling, inotropic activity and vascular tone [5, 6].
Cardiotonic steroids are known to play a key role in sodium excretion in response to volume
expansion. Their effect is primarily mediated through binding to the Na/K-ATPase, a ubiqui‐
tous membrane ion transporter and a crucial protein in controlling the electrochemical
gradient in cells. Recently, our understanding of the interaction between cardiotonic steroids
and the Na/K-ATPase has undergone re-evaluation, and it has since been proposed that this
binding leads to the generation of a signaling cascade, which not only produces the natriuretic
response in dealing with volume expansion, but may also offer an explanation for the pro-
fibrotic effects of cardiotonic steroids.
For many years, the understanding of renal physiology and the kidney’s role in maintaining
volume homeostasis revolved around the renin-angiotensin-aldosterone pathway, its effects
on the glomerular filtration rate as well as contributions from the sympathetic nervous system.
Standard therapies offered for congestive heart failure are mostly limited to modulation of this
neurohumoral axis through drug therapy. However, this has been inadequate in explaining
how volume expansion is handled by the body [7, 8]. In 1961, de Wardener introduced an
entirely new concept in renal hemodynamics when he discovered that kidneys were still able
to increase sodium excretion after saline infusion despite controlling glomerular filtration rate
and aldosterone [9]. Thus, it was proposed that a “Third Factor” was also in play, named for
its discovery after glomerular filtration rate (Factor-1) and aldosterone (Factor-2). Uncovering
this “Third Factor” galvanized great interest over the next two decades, and significant
contributions from Schrier, Kramer, Bricker, Gruber, and others resulted in our current
understanding that the “Third Factor” was in fact a circulating endogenous digitalis-like
substance, now commonly referred to as a cardiotonic steroid (CTS) [10-14]. CTS include plant-
derived cardenolides such as ouabain and digoxin, and amphibian-derived bufadenolides
such as marinobufagenin and proscillaridin A [15-18]. Ouabain and marinobufagenin were
identified as endogenous hormones after they were detected in human plasma and urine
[15-19]. Coincidentally, along with the fervent CTS research in renal physiology, many
scientists were also interested in the role ouabain played as an ionotropic agent in myocardium.
In 1963, Repke was the first to suggest the Na/K-ATPase was a receptor for these drugs [20].
Since then, extensive studies from many laboratories revealed that these compounds were
specific ligands for the Na/K-ATPase, and in fact, produced their natriuretic and ionotropic
effects through binding to the Na/K-ATPase [21].
2.1. Na/K-ATPase inhibition and CTS-regulated natriuresis
The Na/K-ATPase was discovered in 1957 by Jens Skou through his studies on crab nerves, and
is a member of the P-type ATPase family responsible for the exchange of Na and K ions across
cell membranes via the hydyolysis of ATP [22]. Its structure and function has since been exten‐
sively studied. It consists of a non-covalently linked alpha and beta subunit, of which multiple
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isoforms in various combinations exist [23]. Four alpha isoforms and three beta isoforms have
been identified and their expression is tissue-specific, as well as their sensitivity to CTS. The al‐
pha-1 isoform appears to be the main functional receptor for CTS in the kidney [24-28].
When de Wardener first considered the possibility of a “Third Factor,” ion pumping was the
only function attributed to the Na/K-ATPase. Thus classically, the mechanism of CTS-induced
natriuresis was understood as follows: volume expansion or a salt-heavy diet leads to an
increase in circulating CTS, which in turn results in the inhibition of the Na/K-ATPase in the
nephron, specifically, its ion pumping ability. Consequently, cytosolic Na+ begins to rise, and
eventually this disruption in the Na+ gradient across the cell membrane decreases Na reab‐
sorption in the renal proximal tubules (RPT) leading to increased sodium excretion. Systemi‐
cally, increased levels of CTS also inhibit the Na/K-ATPase in vasculature, thereby altering
intracellular Na gradients in vascular smooth muscle cells. This indirectly leads to the
inhibition of the Na/Ca exchanger causing intracellular calcium in these smooth muscle cells
to rise as well [29-31]. Chronically, this leads to an important trade-off. Despite its pivotal role
in renal salt handling, this pathway has substantial consequences in the vasculature and has
been implicated in the pathogenesis of hypertension [29-31] (Figure 1).
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Figure 1. Ionic Mechanism for CTS Induced Hypertension
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2.2. CTS and Na/K-ATPase-mediated signal transduction
In the late 1990’s, Xie and colleagues suggested that the Na/K-ATPase had an additional
signaling function in addition to its  transportation of  ions.  He proposed that  instead of
only  inhibiting  the  pumping  activity  of  the  Na/K-ATPase,  CTS  also  bound  to  a  non-
pumping pool of Na/K-ATPase residing in caveolae [32]. This subset of Na/K-ATPase in‐
nately  held Src,  a  non-receptor  tyrosine  kinase,  in  an inactive  state.  With the  structural
change  induced by  CTS binding,  Src  was  subsequently  released and activated.  In  turn,
EGFR became transactivated and a number of additional downstream targets in the sig‐
naling  cascade  such  as  Ras/Raf/MAPK,  PI3  kinase/Akt,  phospholipase  C/PKC,  and  the
generation of ROS have been identified [33-40].
3. Uremic cardiomyopathy
It is well substantiated that cardiovascular mortality remains the leading cause of death in
patients with end stage renal disease with the majority of the cases due to sudden cardiac death
and coronary events [1]. While traditional risk factors associated with cardiac dysfunction exist
in patients with renal failure the risk conferred can exceed twice that of normal patients [41].
The risk of cardiovascular disease is not limited to those with end stage renal failure but rather
confers a gradual risk of increased cardiovascular and all-cause mortality as glomerular filtrate
rate declines and albuminuria increases [42]. Systolic dysfunction in these patients have been
less consistently demonstrated [43] but rather the development of LVH is more common and
may be a predictor of higher mortality related to arrhythmia and sudden death in patients on
dialysis [44]. The myocardial fibrosis initially described with uremia as early as 1943 by Rossle
and later characterized by Ritz et al has a pivotal role in the development of uremic cardio‐
myopathy [45]. While traditional thought regarding cardiac fibrosis revolved around a
reparative process related to myocardial necrosis; early fibrosis after subtotal nephrectomy
without myocardial necrosis has been demonstrated suggesting the potential for a reactive
process rather reparative. Mall and colleagues utilizing a uremic cardiomyopathy model in
rats demonstrated that interstitial volume density increased with a resultant decrease in the
capillary volume. Additionally, cytoplasmic and nuclear swelling occurred whereas the
endothelial cells remained unchanged [46]. This reactive cardiac fibrosis can explain the
alterations in left ventricular compliance in addition to the electrical conduction abnormalities
causing arrythmogenic potential. The risk factors in patients with chronic renal failure believed
to be involved in cardiac fibrosis and LVH include anemia, activation of the RAS aldosterone
system, oxidative stress, hyperparathyroidism, hypertension and cardiotonic steroids.
4. Natriuresis versus fibrosis—A new trade-off model
The activation of Na/K-ATPase signaling by CTS also appears to be responsible for the
coordinated inhibition of Na+ transporters in the nephron resulting in natriuresis. This concept
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is not without precedence. Dopamine, another known natriuretic hormone, increases sodium
excretion through signal transduction by mediating the synchronized downregulation of
basolateral Na/K-ATPase and apical Na/H antiporter isoform-3 (NHE3) after binding to D1
and D2 receptors in the nephron [47, 48]. Similarly, Liu and Shapiro as well as others noted
that CTS at physiological concentrations activated the previously described signaling cascades,
resulting in the endocytosis of both the basolateral Na/K-ATPase and apical NHE3 in cultured
renal epithelial cells. As a result, this redistribution of membrane Na+ transporters in RPTs
leads to a reduction in sodium reabsorption and increased sodium excretion [49-53].
Support for this theory has also been demonstrated in vivo. Lingrel first established that
ouabain binding to the Na/K-ATPase is crucial in the natriuretic response of the kidney.
His laboratory developed ouabain-sensitive mice by incorporating a mutation in the oua‐
bain receptor domain of the mouse alpha-1 Na/K-ATPase and noted that saline infusion
increased the natriuretic response in ouabain-sensitive in comparison to ouabain-resistant
mice [54]. More recently, Nascimento showed that bufalin—another derivative of the bu‐
fadenolides—required  Na/K-ATPase  signaling  in  order  to  produce  natriuretic  effects  in
isolated  rat  kidneys  [55].  Studies  from  our  laboratories  also  found  that  high-salt  diets
cause  the  endocytosis  of  Na/K-ATPase  in  rat  proximal  tubules,  correlating  with  an  in‐
crease in Na+ excretion [56]. More recently, we demonstrated that high-salt diets in Dahl
salt-resistant  mice  (R)  induced  the  endocytosis  of  RPT  Na/K-ATPase  and  NHE3  trans‐
porters  concurrent  with  increased  Src  activity.  In  contrast,  Na/K-ATPase  signaling  was
not activated in Dahl salt-sensitive mice (S) [57].
To re-emphasize, natriuresis due to Na/K-ATPase signaling is a markedly different model from
that of the classic pathway. Here, intracellular Na+ is unaffected by the coupling of CTS to the
Na/K-ATPase, and instead, signal transduction is responsible for the effects on Na+ transport
in RPTs. This alternate pathway also presents distinct tradeoffs from those of the classic
pathway (i.e. hypertension). More specifically, natriuresis through CTS-Na/K-ATPase
signaling appears to lead to the development of fibrosis in cardiac and renal organs. Of note,
previous experiments have already implicated CTS in the hypertrophic growth of cardiac cells
[58-65]. Also taking into account the well-established effects of the Src tyrosine kinase in cell
growth and differentiation, it is conceivable to suggest a role of CTS in organ remodeling.
Remarkably, this phenomenon of fibrosis development has recently been supported by both
in vivo and in vitro studies from our laboratory and others.
Using partial (5/6th) nephrectomy models, which have been utilized for many years to simulate
renal failure, we noted that the development of cardiac fibrosis in both rats and mice was
mediated by an increase in systemic oxidative stress as well as increased levels of circulating
MBG [2, 66-68]. Presumably, this suggests that the CTS-induced fibrosis appears to be
dependent on Na/K-ATPase signaling leading to the generation of ROS, thus causing oxidative
stress to cardiac and renal tissues. This finding in the animal models corresponded to evidence
of signaling through the Na/K-ATPase as we detected activation of both Src and MAPK
phosphorylation in the fibrotic cardiac tissue [2, 67]. These results were similarly demonstrated
in rats subjected to MBG infusion [2, 67]. Remarkably, after adrenalectomy to lower circulating
levels of MBG and active immunization against an MBG-albumin conjugate, cardiac fibrosis
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was significantly reduced in both partial nephrectomy and MBG-infusion experimental
groups [2, 66-68].
In a separate set of experiments, Wansapura subjected genetically altered ouabain-sensitive
mice (originally developed by Lingrel) to aortic banding in order to simulate a pressure
overload model. After four weeks, the ouabain-sensitive group was noted to have developed
substantially greater cardiac hypertrophy and fibrosis compared to ouabain-resistant (wild-
type) mice. Furthermore, the administration of Digibind to the ouabain-sensitive mice
diminished these cardiac changes [69].
Additional in-vivo data support the potential for a more significant reversal of cardiotonic
steroid associated hypertension, cardiac hypertrophy and oxidative stress through utilization
of a monoclonal antibody (mAb). Haller subjected partially nephrectomized rats demonstrat‐
ing elevated levels of MBG to mAb with a high affinity for MBG and Digibind. Both treatments
resulted in significant improvement in cardiac hypertrophy, hypertension and measures of
oxidative stress. While both therapies demonstrated similar responses there were significantly
better results with the MGG directed monoclonal antibody [70].
Furthermore, in cultures of rat cardiac and renal fibroblasts as well as human dermal fibro‐
blasts, we found that both ouabain and MBG were able to directly increase collagen production
and proline incorporation [67, 71, 72]. By inducing a translocation of PKC to the nucleus, MBG
appears to cause the subsequent phosphorylation and degradation of Friend leukemia
integration-1 (Fli-1), which Watson and colleagues have demonstrated is a negative regulator
of collagen synthesis in dermal fibroblasts [71, 73]. In fact, we found MBG reduced Fli-1
expression and increased procollagen-1 in all three of our fibroblast cell lines (cardiac, renal,
dermal) [71]. Furthermore, MBG infusion stimulates the expression and nuclear translocation
of Snail, a transcription factor involved in epithelial-mesenchymal transition, which is
implicated in renal fibrosis [74].
Similar to the animal studies, these findings in cell culture have corresponded with increased
Na/K-ATPase signaling activity and the generation of ROS, which notably was successfully
blocked by both ROS scavengers and Src inhibitors [67]. In addition, we examined the effects
of spironolactone—known to be a competitive antagonist of CTS binding to the Na/K-ATPase
—as well as its major metabolite, canrenone. Corroborating with our hypothesis, we found
that spironolactone significantly attenuated cardiac fibrosis in the renal failure models, and
both spironolactone and canrenone reduced collagen production in cardiac fibroblasts. It was
further demonstrated that MBG-induced Na/K-ATPase signaling was blocked in these
experiments [75].
5. Conclusions
Endogenous circulating CTS such as ouabain and MBG are known to be upregulated in the
body’s stress response towards volume expansion. Binding to its receptor—the Na/K-ATPase
—leads to increased sodium excretion in the proximal tubules of the nephron. Whether this is
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accomplished through the classic ionic pathway, the alternate signaling pathway, or both is
still debated; however, its effect on re-establishing volume homeostasis is undeniable. Like
many other physiological processes, the fine-tuning of one pathway may result in unintended
consequences elsewhere in the body. In the case of CTS-induced natriuresis through Na/K-
ATPase signaling, the tradeoff is apparent in the development of cardiac and renal fibrosis as
demonstrated both in vivo and in vitro (Figure 2). Because the fibrosis appears to be dependent
on Na/K-ATPase signaling, the generation of ROS, and subsequent oxidative stress to cardiac
and renal tissues, this creates the potential for both new and old drugs to target and block the
signaling cascade. ROS scavengers, Src inhibitors, spironolactone, and canrenone have already
demonstrated exciting possibilities in our experiments. Further research in developing more
specific CTS antagonists as well as whether this concept can be extrapolated to humans needs
to be explored. Interestingly, in the late 1990’s and early 2000’s, Pitt and colleagues conducted
the Randomized Aldactone Evaluation Study (RALES), followed by the Eplerenone Post–
Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and
determined that spironolactone and eplerenone, respectively, were cardioprotective in
patients with advanced stages of congestive heart failure [76, 77]. More recently, the Eplere‐
none in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)
and the Anti-Remodeling Effect of Canrenone in Patients with Mild Chronic Heart Failure
(AREA IN-CHF) trials found further therapeutic benefit in patients with mild (NYHA Class
II) CHF [78, 79]. These clinical studies proposed that the anti-aldosterone effects were primarily
responsible for the reduction in morbidity and mortality; however, it is certainly plausible to
speculate whether these drugs as Na/K-ATPase signaling inhibitors may have also played a
role. Nonetheless, CTS-induced signaling through the Na/K-ATPase is a significant and novel
link in balancing the hemodynamics of salt handling and the development of fibrosis.
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